Valiant Organics Ltd
Incorporated in 1984, Valiant Organics
Ltd manufactures and deals in specialty chemicals and pharma intermediates[1]
- Market Cap ₹ 955 Cr.
- Current Price ₹ 341
- High / Low ₹ 456 / 225
- Stock P/E
- Book Value ₹ 237
- Dividend Yield 0.00 %
- ROCE 0.96 %
- ROE -1.14 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 2.26% over past five years.
- Company has a low return on equity of 8.94% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Chemicals Industry: Chemicals
Part of BSE SmallCap BSE Commodities BSE Allcap
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
34 | 43 | 59 | 52 | 73 | 121 | 606 | 584 | 574 | 948 | 912 | 677 | 692 | |
28 | 34 | 48 | 36 | 55 | 94 | 426 | 410 | 417 | 783 | 782 | 638 | 660 | |
Operating Profit | 6 | 8 | 11 | 16 | 18 | 26 | 179 | 174 | 157 | 165 | 130 | 40 | 32 |
OPM % | 18% | 19% | 19% | 30% | 25% | 22% | 30% | 30% | 27% | 17% | 14% | 6% | 5% |
1 | 1 | 1 | 1 | 2 | 1 | 5 | 5 | 17 | 6 | 8 | 9 | 10 | |
Interest | 0 | 1 | 1 | 0 | 0 | 0 | 2 | 1 | 3 | 6 | 11 | 19 | 26 |
Depreciation | 1 | 1 | 1 | 1 | 2 | 2 | 12 | 13 | 19 | 27 | 28 | 34 | 35 |
Profit before tax | 6 | 8 | 11 | 16 | 18 | 25 | 171 | 165 | 152 | 137 | 100 | -5 | -20 |
Tax % | 34% | 32% | 34% | 35% | 35% | 35% | 29% | 25% | 25% | 25% | 24% | -41% | |
4 | 6 | 7 | 10 | 12 | 16 | 121 | 124 | 115 | 103 | 76 | -3 | -18 | |
EPS in Rs | 57.57 | 79.14 | 103.86 | 14.03 | 15.92 | 13.97 | 103.65 | 51.00 | 42.20 | 37.91 | 27.83 | -1.10 | -6.38 |
Dividend Payout % | 38% | 27% | 50% | 71% | 16% | 23% | 6% | 11% | 12% | 9% | 4% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 32% |
5 Years: | 2% |
3 Years: | 6% |
TTM: | -5% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -160% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | -13% |
3 Years: | -23% |
1 Year: | -20% |
Return on Equity | |
---|---|
10 Years: | 20% |
5 Years: | 15% |
3 Years: | 9% |
Last Year: | -1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 0.36 | 0.36 | 0.36 | 4 | 4 | 6 | 6 | 12 | 27 | 27 | 27 | 28 | 28 |
Reserves | 15 | 18 | 21 | 19 | 42 | 53 | 254 | 374 | 475 | 576 | 638 | 637 | 626 |
2 | 5 | 8 | 1 | 1 | 1 | 53 | 119 | 150 | 306 | 220 | 216 | 165 | |
10 | 14 | 11 | 17 | 23 | 36 | 89 | 125 | 154 | 174 | 220 | 262 | 254 | |
Total Liabilities | 28 | 37 | 40 | 41 | 69 | 96 | 402 | 629 | 806 | 1,083 | 1,106 | 1,142 | 1,073 |
10 | 11 | 11 | 12 | 26 | 31 | 130 | 256 | 478 | 509 | 610 | 630 | 625 | |
CWIP | 0 | 0 | 1 | 0 | 0 | 0 | 66 | 129 | 46 | 110 | 70 | 86 | 90 |
Investments | 2 | 2 | 2 | 2 | 7 | 7 | 20 | 34 | 42 | 53 | 53 | 54 | 55 |
15 | 24 | 26 | 26 | 35 | 58 | 187 | 210 | 240 | 410 | 373 | 371 | 303 | |
Total Assets | 28 | 37 | 40 | 41 | 69 | 96 | 402 | 629 | 806 | 1,083 | 1,106 | 1,142 | 1,073 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
8 | 3 | 6 | 18 | 9 | 18 | 77 | 160 | 115 | -11 | 183 | 85 | |
-3 | -2 | -1 | -1 | -1 | -6 | -88 | -191 | -135 | -120 | -91 | -65 | |
-5 | -2 | -5 | -16 | -4 | -5 | 2 | 35 | 22 | 146 | -109 | -23 | |
Net Cash Flow | -0 | -2 | -0 | 0 | 4 | 7 | -8 | 5 | 1 | 14 | -17 | -3 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 71 | 90 | 74 | 71 | 88 | 112 | 73 | 69 | 74 | 97 | 85 | 113 |
Inventory Days | 45 | 94 | 42 | 36 | 97 | 44 | 45 | 47 | 85 | 58 | 69 | 91 |
Days Payable | 91 | 81 | 7 | 50 | 130 | 154 | 80 | 97 | 135 | 76 | 100 | 166 |
Cash Conversion Cycle | 25 | 103 | 110 | 57 | 55 | 2 | 37 | 20 | 25 | 80 | 54 | 38 |
Working Capital Days | 5 | 44 | 101 | 66 | 70 | 42 | 55 | 34 | 51 | 90 | 68 | 68 |
ROCE % | 37% | 43% | 43% | 61% | 52% | 48% | 91% | 41% | 27% | 18% | 12% | 1% |
Documents
Announcements
-
Update On Related Party Transaction Limits
9 May - Revised related party transaction limits with Aarti Pharmalabs approved, cancelling earlier higher limits.
-
Announcement under Regulation 30 (LODR)-Credit Rating
8 May - CRISIL reaffirms Valiant Organics' Rs. 370 Cr bank loan ratings: A- /Negative and A2+.
-
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 ("Listing Regulations") - Action Taken Or Order Passed
3 May - Income Tax penalty of Rs. 87.92 lakh for AY 2020-21; company to appeal.
-
Announcement under Regulation 30 (LODR)-Acquisition
24 Apr - Valiant Organics invests Rs.2.9 Cr for 26.25% stake in renewable energy SPV for captive solar power.
-
Announcement under Regulation 30 (LODR)-Change in Management
19 Apr - Independent director Mulesh Savla completes second term and ceases on April 19, 2025
Annual reports
Concalls
-
Feb 2025TranscriptNotesPPT
-
Dec 2024TranscriptNotesPPT
-
Aug 2024TranscriptNotesPPT
-
Jun 2024TranscriptNotesPPT
-
May 2024TranscriptNotesPPT
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT
-
Sep 2023Transcript PPT
-
Aug 2023TranscriptNotesPPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Nov 2022TranscriptNotesPPT
-
Sep 2022TranscriptNotesPPT
-
Aug 2022Transcript PPT
-
Jul 2022TranscriptNotesPPT
-
May 2022Transcript PPT
-
Mar 2022TranscriptNotesPPT
-
Mar 2022TranscriptNotesPPT
-
Feb 2022TranscriptNotesPPT
-
Sep 2021TranscriptNotesPPT
Business Overview:[1][2][3]
VOL is is promoted by Gogri, Chedda and Gala families. It manufactures specialty chemicals and is one of the largest manufacturers of chlorophenol derivatives, Benzene derivatives, PNA, PAP, Ortho Anisidine and Para Anisidine.
Product Portfolio[4]
1. Ammonolysis
Products include Para Nitro Aniline and Ortho Chloro Para Nitro Aniline, primarily serving the dyes and pigments industries.
2. Hydrogenation
The product range comprises Ortho Anisidine, Para Anisidine, IPPCA, Meta Chloro Aniline, Para Amino Phenol, and Ortho Amino Phenol, catering to dyes, pigments, pharmaceuticals, and agrochemicals sectors.
3. Chlorination
Key products are Para ChloroPhenol (PCP), Ortho ChloroPhenol (OCP), 2,4 Di ChloroPhenol (2,4 DCP), 2,6 Di ChloroPhenol (2,6 DCP), and 2,4,6 Tri ChloroPhenol (2,4,6 TCP), widely used in agrochemicals, cosmetics, veterinary, and pharmaceutical applications.